Asset
Esmethadone
Relmada Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04688164 | phase3 | completed | 2021-01-08 | 2022-11-01 | Relmada Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) |
| NCT05081167 | phase3 | completed | 2021-06-02 | 2022-09-13 | Relmada Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) |
| NCT04855760 | phase3 | completed | 2021-04-01 | 2023-07-27 | Relmada Therapeutics, Inc. | Safety of REL-1017 for Major Depressive Disorder |
| NCT03637361 | phase1 | completed | 2014-12-04 | 2015-06-02 | Relmada Therapeutics, Inc. | Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone) |
| NCT03051256 | phase2 | completed | 2018-05-11 | 2019-07-30 | Relmada Therapeutics, Inc. | Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD |
FDA applications (0)
This company has no applications containing this asset.